Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data
Patrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2 1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USACorrespondence: Patrick M DillonDivision of Hematology/Oncology, Univ...
Guardado en:
Autores principales: | Dillon PM, Brenin CM, Slingluff CL Jr |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8f13b704edc548b7967b873fe2665815 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021) -
Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
por: Ayoub NM, et al.
Publicado: (2019) -
Single-day HER2neu amplification assessment using chip-based digital PCR in formalin-fixed paraffin-embedded breast carcinoma tissue
por: Shah PS, et al.
Publicado: (2018) -
Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
por: Xiaoshuang Lyu, et al.
Publicado: (2021) -
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
por: Antolín S, et al.
Publicado: (2018)